

Characterization of *Klebsiella pneumoniae* isolated from patients suspected of pulmonary or bubonic plague during the Madagascar epidemic in 2017

Andriniaina Rakotondra (✉ aina@pasteur.mg)

Experimental bacteriology unit, Institut Pasteur Madagascar, Antananarivo

Lova Andrianonimiadana

Experimental bacteriology unit, Institut Pasteur Madagascar, Antananarivo

Soloandry Rahajandraibe

Plague unit, Institut Pasteur Madagascar, Antananarivo

Solohery Razafimahatratra

Experimental bacteriology unit, Institut Pasteur Madagascar, Antananarivo

Voahangy Andrianaivoarimanana

Plague unit, Institut Pasteur Madagascar, Antananarivo

Soanandrasana Rahelinirina

Plague unit, Institut Pasteur Madagascar, Antananarivo

Tania Crucitti

Experimental bacteriology unit, Institut Pasteur Madagascar, Antananarivo

Sylvain Brisse

Biodiversity and Epidemiology of Bacterial Pathogens, Institut Pasteur, Paris

Victor Jeannoda

Mention Biodiversité et Santé, Sciences Faculty, University of Antananarivo

Minoarisoa Rajerison

Plague unit, Institut Pasteur Madagascar, Antananarivo

Jean-Marc Collard

Experimental Bacteriology Laboratory, Center for Microbes, Development and Health (CMDH), Institut Pasteur of Shanghai/Chinese Academy of Sciences

Research Article

Keywords: *Klebsiella pneumoniae*, pneumopathy, bubo, community-acquired pneumonia, virulent clone.

Posted Date: May 3rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-449539/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Characterization of *Klebsiella pneumoniae* isolated from patients suspected of**
2 **pulmonary or bubonic plague during the Madagascar epidemic in 2017**

3

4 **Andrianiaina Rakotondraso^{1*}, Lova Maminirina Andrianonimiadana,¹ Soloandry**
5 **Rahajandraibe,² Solohery Razafimahatratra,¹ Voahangy Andrianaivoarimanana,²**
6 **Soanandrasana Rahelinirina,² Tania Crucitti,¹ Sylvain Brisse,³ Victor Jeannoda,⁴**
7 **Minoarisoa Rajerison,^{2#}, Jean-Marc Collard.^{1#a}**

8

9 ¹ Experimental bacteriology unit, Institut Pasteur Madagascar, Antananarivo, Madagascar;

10 ² Plague unit, Institut Pasteur Madagascar, Antananarivo, Madagascar;

11 ³ Biodiversity and Epidemiology of Bacterial Pathogens, Institut Pasteur, Paris, France;

12 ⁴ Mention Biodiversité et Santé, Sciences Faculty, University of Antananarivo, Madagascar

13 ^a Current address: Experimental Bacteriology Laboratory, Center for Microbes, Development
14 and Health (CMDH), Institut Pasteur of Shanghai/Chinese Academy of Sciences, People's
15 Republic of China

16

17 *Correspondence author: aina@pasteur.mg; Tel.: +261 34 98 185 32

18 # These authors contributed equally to this work

19 **Abstract**

20 *Klebsiella pneumoniae* can lead to a wide range of diseases including pneumonia,
21 bloodstream and urinary tract infections. During a short period of a plague epidemic in
22 October 2017 in Madagascar, 12 *K. pneumoniae* isolates were identified in ten sputum and
23 two buboes aspirate samples. These isolates were from 12 patients suspected of plague,
24 without epidemiological relationships, but were negative for *Yersinia pestis* in culture. Data
25 were collected from the plague national surveillance system. The isolates were characterized
26 by antimicrobial susceptibility testing and whole-genome sequencing. Real-time PCR was
27 performed to confirm the presence of *K. pneumoniae* DNA in buboes. All isolates were
28 identified as *K. pneumoniae* sensu stricto. Five isolates were extended-spectrum β -
29 lactamases producers; eight different sequence types were identified. Five isolates belonged
30 to known hypervirulent sequence types. Our results demonstrate community-acquired
31 pneumonia caused by *K. pneumoniae* isolates in patients suspected of plague, showing that
32 plague epidemics can hide other etiologies.

33

34 **Keywords:** *Klebsiella pneumoniae*, pneumopathy, bubo, community-acquired pneumonia,
35 virulent clone.

36

37

38

39

40 **Background**

41 Between August 1 and November 26, 2017; a total of 2.414 clinically suspected plague
42 cases were reported to the Central Laboratory for Plague (CLP) at the Institut Pasteur de
43 Madagascar, including 1.878 (78%) pulmonary plague (PP), 395 (16%) bubonic plague (BP),
44 one (<1%) septicaemia and 140 (6%) cases with unspecified clinical form¹. This
45 predominantly urban plague epidemic was characterised by a large volume of notifications in
46 two major urban areas (Antananarivo and Toamasina) and by an unusually high proportion of
47 pneumonic forms. According to the 2006 WHO standard plague case definitions and using
48 the results of three types of diagnostic tests assessed (rapid F1-antigen diagnostic test,
49 (RDT), molecular amplification method, and culture)², 386/1.878 (21%) were probable and
50 32/1.878 (2%) were confirmed cases among the notified PP cases. The magnitude of this
51 pneumonic plague outbreak is likely to have been smaller that suggested by notified
52 suspected cases¹; and its severity indicated by the case fatality rate among confirmed plus
53 probable (about 9%) was substantially lower than observed the last previous 18 years
54 (25%)³. Over-reporting of PP cases due to limited clinical experience two most affected
55 areas, and the difficulty to clinically diagnose PP through respiratory signs was speculated.
56 The clinical diagnosis of pneumonic plague from polymicrobial sputum associated with other
57 potential causes of pneumonia remains a challenge because the isolation of *Yersinia pestis*
58 (*Y. pestis*) is more complicated compared to other bacteria.

59 *Klebsiella pneumoniae* (*K. pneumoniae*) is a Gram-negative bacterium naturally resistant to
60 amoxicillin and carbenicillin. *Klebsiella pneumoniae* complex members comprise 7
61 phylogroups (Kp1 to Kp7) with *K. pneumoniae* sensu stricto, *K. quasipneumoniae* subsp.
62 *quasipneumoniae*, *K. quasipneumoniae* subsp. *similipneumoniae*, *K. variicola* subsp.
63 *variicola*, *K. variicola* subsp. *tropica*, *K. quasivariicola*, and *K. africana*, respectively⁴. It has
64 become an important MDR pathogen of the last decade with multiple resistance
65 determinants, mostly for aminoglycosides, cephalosporins and carbapenems⁵. It has been

66 isolated from hospital-acquired infections including pneumonia, bloodstream infection,
67 urinary tract infection, and community acquired infections such as hepatic abscess and
68 meningitis and pneumonia. The capsule is an important virulence factor that protects *K.*
69 *pneumoniae* from phagocytosis, with over 79 defined capsular serotypes. Isolates with K1
70 and K2 capsular serotypes are associated with virulent infections. However, not all K2
71 capsular isolates are virulent. In this regard, virulence was confirmed in murine models⁶.
72 Virulence factors associated with hypervirulent *Klebsiella* infections include siderophores,
73 virulence plasmid encoding aerobactin, salmochelin, yersiniabactin, and the
74 hypermucoviscosity factor *mpA/mpA2* gene⁷⁻¹².
75 Here we report on the characterization of a series of 12 *K. pneumoniae* isolated from the
76 sputum and bubo aspirates from clinically suspected plague patients during the plague
77 outbreak in Madagascar, 2017.

78

79 **Material and methods**

80 **Patients and bacterial isolates**

81 Patients with confirmed *K. pneumoniae*, isolated during nine days of the plague epidemic
82 (from the 6th of October 2017 till the 14th of October 2017), were included in this sub-study.
83 Epidemiological, clinical and lab data of patients were extracted from the plague national
84 surveillance system database of Institut Pasteur de Madagascar between August 1st and
85 November 26th in 2017¹. *Y. pestis* was isolated from biological samples (bubo aspirates for
86 bubonic plague, sputum for pneumonic plague) by direct culture on *Yersinia* selective
87 Cefsulodin-Irgasan-Novobiocin (CIN) agar medium (Oxoid Ltd., United Kingdom). All
88 methods were carried out according to the 2006 WHO recommendations¹³. Culture
89 incubation was done at 26–28°C for 48h or longer as *Y. pestis* grows slower than other
90 bacteria. Colonies obtained within 24 h on CIN medium and which did not have *Y. pestis*
91 morphology were identified on MALDI-TOF MS (Biotyper version 3.3, Bruker Daltonics,

92 Champs-sur-Marne, France). Colonies identified as *K. pneumoniae* were further purified on
93 Simmons Citrate Agar Inositol (SCAI) medium¹⁴.

94

95 **Phenotype detection**

96 The hypermucoviscosity phenotype of the *K. pneumoniae* isolates was determined using the
97 string test, in which a standard bacteriological loop is used to stretch a mucoviscous string
98 from each colony cultured on SCAI medium. The formation of a viscous string > 5 mm in
99 length was regarded as a positive test result¹².

100

101 **Bacterial susceptibility testing**

102 Antibiotic resistance profiles were determined by the standard disc diffusion method
103 according to CASFM-EUCAST V2-0-May2017 guidelines and using breakpoints for
104 *Enterobacteriaceae* (<http://www.sfm-microbiologie.org>). Isolates were tested against 17
105 commonly used antimicrobial agents, namely amoxicillin, amoxicillin-clavulanate,
106 piperacillin/tazobactam, cefalotin, cefoxitin, cefotaxime, ceftazidime, cefepime, aztreonam,
107 imipenem, ertapenem, tobramycin, gentamicin, nalidixic acid, ciprofloxacin, trimethoprim-
108 sulfamethoxazole and tetracycline. In addition, extended spectrum β -lactamase (ESBL)
109 production was tested using the standard double disc synergy test.

110

111 **Genome sequencing and analysis**

112 Genomic DNA of the *K. pneumoniae* isolates was extracted using DNeasy Blood & Tissue kit
113 (Qiagen, Germany) and was subjected to whole genome sequencing. Genomic libraries were
114 constructed using the Nextera XT DNA library preparation kit with dual indexing (Illumina,
115 San Diego, USA). The libraries were sequenced on an Illumina NextSeq-500. Genome
116 assembly was performed *de novo* using Spades Genome Assembler (Version 3.10.0).
117 Genome analyses for core genome MLST (cgMLST) on 632 core gene were performed,

118 sequence types (ST), virulence genes, and capsular serotypes (K-types) were assigned
119 using the *Klebsiella pneumoniae* database hosted through the BIGSdb web application of the
120 Institut Pasteur in Paris (<https://bigsdb.pasteur.fr/klebsiella>). Antimicrobial resistance genes
121 were identified from genome sequences using the Resfinder (version 3.2). Plasmid replicon
122 types were determined by using the Plasmidfinder (version 2.0) tool at
123 <https://genomicepidemiology.org/>. RAxML and parsnp were used to draw the tree. The
124 Gubbins software tool was used to remove the single nucleotide polymorphisms (SNPs) on
125 recombined regions and to create a phylogenetic tree using Maximum Likelihood. The tree
126 was subsequently annotated with iTOL.

127

128 **Buboes *K. pneumoniae* screening by real-time PCR**

129 We performed a real-time PCR targeting the *zur-khe* intergenic region¹⁵ on the bubo samples
130 in order to confirm the presence of *K. pneumoniae* DNA in the bubo and to exclude any
131 technical contamination during culture. Bacterial DNA was extracted from the bubo samples
132 using DNeasy Blood & Tissue kit (Qiagen, Germany). The real-time PCR assay was
133 performed as previously described with the difference that we used 10 µl of Sso Advanced
134 universal SYBR Green Supermix (Bio-Rad, USA)¹⁵. Amplifications were performed using the
135 CFX-96 (BIO-RAD, USA) platform. The positive controls consisted of DNA from *K.*
136 *pneumoniae* UAA2239 and UAA2016 which are reference strains from the National
137 Reference Center for Antibiotics from the Institut Pasteur in Paris, the negative control was
138 plain molecular grade water.

139

140 **Ethics statement**

141 No additional ethical clearance was requested because the analysis was carried out within
142 the framework of the national surveillance system. No additional data was collected.

143 All patients provided oral consent and voluntarily agreed for sampling for diagnostic
144 purposes.

145

146 **Nucleotide sequence accession numbers**

147 WGS data have been deposited at the National Center for Biotechnology Information (NCBI)
148 under BioProject PRJNA565154.

149

150 **Results**

151 **Case presentation and *Klebsiella pneumoniae* antimicrobial susceptibility**

152 *K. pneumoniae* was isolated from 12 clinical samples out of 496 collected between 06 and 14
153 October 2017 in Antananarivo (N=362) and Toamasina (N=134) and screened for *Y. pestis*
154 presence by culture. This period was reported as the peak of the plague epidemic curve, with
155 essentially pneumonic plague cases. Patients had early clinical signs suggesting pulmonary,
156 secondary pulmonary or bubonic plague in an epidemic setting.

157 The samples containing *K. pneumoniae* were 10 sputum samples and two bubo aspirates
158 and were negative for *Y. pestis* colonies. The description of the 12 patients is shown in
159 (Table 1). Two-thirds of the patients (N=8) were from Antananarivo and one-third (N=4) was
160 from Toamasina. Seven patients were men. Five patients were younger than 18 years, and
161 six were 19 to 27 years old and one was 46 years old. Fever status was reported for 10
162 patients, eight of them had body temperatures >37.5°C. According to the clinical forms, nine
163 patients were suspected of having pulmonary plague and one was defined to suffer from
164 secondary pulmonary plague. One patient was suspected of bubonic plague and for another
165 patient, data about the clinical form was lacking.

166 Four of the patients coughed for at least 5 days and complained of chest pain, although they
167 were in an overall good state of health. Two patients had signs of hemoptysis, and one of

168 them was in weak health. Two patients coughed without further complaints but one was in
169 weak health.

170 Four patients were under antibiotic treatment at the time of sample collection: two with
171 trimethoprim-sulfamethoxazole; one with doxycycline and one with gentamicin. One patient
172 who received trimethoprim-sulfamethoxazole was treated in addition with amoxicillin. There
173 was no mortality among these patients (Table 1).

174 Abundant colonies with a typical *K. pneumoniae* morphology (moist, dome-shaped) were
175 recognized after 24h culture on CIN medium. The twelve isolates were identified as *K.*
176 *pneumoniae* by MALDI-TOF. The presence of *K. pneumoniae* DNA in the two bubo samples
177 was also detected by real time-PCR. Melting curve values for the detection of *K. pneumoniae*
178 were 79° and 80° for the positive controls and the DNAs extracted from buboes, respectively
179 (Fig. 2). Of the 12 isolates, four had a positive string test.

180 Five isolates were ESBL producers. Six isolates were resistant to sulfonamides and
181 trimethoprim. Three and two isolates were resistant to gentamycin and tobramycin,
182 respectively. One isolate was resistant to ciprofloxacin (Table 2).

183

184 **Genome analysis**

185 Whole genome sequencing of the *K. pneumoniae* isolates allowed us to characterize
186 cgMLST alleles, virulence genes, capsular loci and resistance genes. All *K. pneumoniae*
187 isolates were *Klebsiella pneumoniae* sensu stricto (Kp1) (Fig 1). Among the 12 isolates eight
188 different sequence types (STs) were identified: ST23 (N=1); ST86 (N=2); ST65 (N=1); ST280
189 (N=1); ST327 (N=1); ST380 (N=1); ST716 (N=1); and ST3012 (N=1), and three new STs:
190 ST3441 (N=1), ST3442 (N=1), ST3443 (N=1) (Table 2). Comparative genomic analysis of
191 the two Kp ST86 isolates showed that they differed from each other by 123 alleles out of 632
192 scgMLST gene loci.

193 The virulence genes identified in most isolates were colibactin locus (*clb*), siderophores
194 (*IroBCDN*), iron uptake systems and regulators (*kfu*, *kvgA*, respectively), yersiniabactin
195 (*fyuA*, *irp1/2* and *ybt*) (Supplementary data). The PP3-ST380-KL1 isolate, two ST86 isolates
196 and the PP11-ST3443-KL2 isolate were positive in string test. All the ST23, ST65, ST86 and
197 ST380 isolates had the genes *rmpA/rmpA2* associated with the hyperproduction of the
198 capsule and also carried the *iucABCD* genes coding for the synthesis of aerobactin
199 (Supplementary Data).

200 Isolates belonging to ST23, ST65, ST86 and ST380 were susceptible to all antibiotics tested,
201 with the exception of amoxicillin to which *K. pneumoniae* is intrinsically resistant.

202 A total of five isolates were ESBL producers (Table 2). A ST280 isolate and a ST3441 isolate
203 carried the *bla*_{CTX-M-15} gene. A ST3442-KL1 isolate harboring virulence genes (*fyu*, *irp1/2*, *ybt*)
204 was ESBL producer and carried the cassette comprising *qnrB66*, *aac (3) -IIa*, *bla*_{SHV-27} and
205 *tet (A)*, as well as the IncFIB_K replicon marker (Table 2).

206

207 **Discussion**

208 Unexpectedly, 12 cases of *K. pneumoniae* infection were detected and identified among
209 individuals clinically suspected to have plague. No *Y. pestis* was identified from their clinical
210 samples, but three patients (PP8, PP10 and PP11) yielded a positive result on RDT.
211 However, culture is the gold standard for the identification of *Y. pestis* and RDT could provide
212 false results¹⁶. All patients had no epidemiological relationships and no family member or
213 contact had been recorded with plague.

214 Although the selective medium for *Yersinia* was not intended for *K. pneumoniae* isolation, *K.*
215 *pneumoniae* does grow on the CIN medium in 24h. The selectivity of this medium is reported
216 as being partial, as other Gram-negative bacilli can grow on CIN medium, including other
217 species of Enterobacterales able to ferment mannitol¹⁷. Therefore, full species identification
218 is recommended.

219 It is not surprising to isolate *K. pneumoniae* from pneumonia cases. Community-acquired *K.*
220 *pneumoniae* infections are common, including in Africa^{18,19}. In contrast, to our best
221 knowledge, *K. pneumoniae* isolated from buboes aspirates were never reported previously.
222 Additionally to culture, the presence of *K. pneumoniae* in buboes aspirates was confirmed by
223 PCR. The advantage of melting curve analysis over Taqman based real time-PCR is its
224 lower costs without losing specificity²⁰. Further studies are needed to evaluate this method,
225 which could be used in screening for *K. pneumoniae* in buboes or other suspected biological
226 samples.

227 *K. pneumoniae* has the capacity to acquire resistance genes and to become increasingly
228 more difficult to treat. One of the *K. pneumoniae* isolates detected in one of two patients who
229 was treated by combination of amoxicillin and trimethoprim-sulfamethoxazole developed
230 resistance. However, *K. pneumoniae* is known to be intrinsically resistant to ampicillin due to
231 the presence of the chromosomal β -lactamase SHV-1 or similar²¹. At the same time, we
232 identified in this strain (ST280), the two genes *dfrA14* and *sul2*, associated to resistance to
233 trimethoprim and sulfamethoxazole, respectively. In addition, among all isolates, it was the
234 only *K. pneumoniae* isolates to be resistant to piperacillin/tazobactam (TZP), which is
235 concordant with the presence of *bla*_{TEM-1B} gene²².

236 Two of the five ESBL isolates harbored *bla*_{CTX-M15}. This gene was commonly found in ESBL-
237 producing *K. pneumoniae* isolated in Madagascar¹⁹. *bla*_{SHV27} and *bla*_{SHV101} were found in the
238 other ESBL-producer.

239 According to MLST analysis, we observed the presence of five STs known to be associated
240 with hypervirulence, including STs ST23 (N = 1), ST65 (N = 1), ST86 (N = 2) and ST380
241 (N=1). In addition, a *K. pneumoniae* isolate having the new ST3443 differs by a single locus
242 from ST86 on the *tonB* locus (allele 18 instead of 27). This strain ST3443 tested string
243 positive, as was also the case for the ST380 and two ST86 strains. Whole genome analysis
244 of *K. pneumoniae* showed that the isolates with common ST differed to each other by alleles

245 occurring outside the 7 household genes. The presence of common virulence genes in the
246 ST23 isolate which were ICEKp10 encoding *clb 2* sequence variants, *ybt 1* and *mpA/mpA2*
247 suggests its belonging to CG23 sublineage I (CG23-I)²³.

248 MLST typing of *K. pneumoniae* isolated in different countries revealed that ST23, ST65,
249 ST86 and ST380 were responsible for hepatic abscess cases and other invasive CA
250 infections²⁴. These isolates have been reported particularly in Asia, but their diffusion outside
251 Asia has been described²⁴. Among virulence factors, *mpA* and aerobactin are the most
252 important one²⁵. The presence of genes responsible for the hypermucoviscosity phenotype,
253 *mpA/mpA2*, plays an important role in the virulence of *K. pneumoniae* isolates. These
254 genes are often associated with serotype K1 and K2. Expression of these genes allows the
255 bacteria to escape the host's defense system and colonize the mucous membranes.

256 Epidemiological studies have shown that the majority of ST23 are related to K1 capsular
257 serotypes and liver abscesses^{23,26}, while K2 is the second capsular serotype resulting in
258 community-acquired pneumonia²⁵. Yersiniabactin, a virulence gene (*Ybt*), detected in the
259 three *K. pneumoniae* isolates serotyped K1 has been reported as the iron absorption system
260 in highly virulent *Y. pestis*²⁷, but was shown to have evolved ancestrally within the *Klebsiella*
261 genus²³. Several studies have shown isolates belonging to these STs (23, 65, 86 and 380),
262 with the same combination of virulence factors, to be virulent in mouse models^{12,23}.

263 During an epidemic, knowledge of the etiology is essential in order to provide the most
264 adapted treatment to patients. Microbiological diagnosis can improve the effectiveness of
265 treatments, avoid long-term complications for the infected patient, and in addition avoid
266 widespread overuse and misuse of antibiotics. Early diagnosis can help to prevent or stop an
267 outbreak too. One of the reasons for a possible treatment failure could arise during
268 inaccurate diagnoses and inappropriate treatments. Similar symptoms can lead to routine
269 treatments based on syndromic approaches which are often applied in developing countries.

270 As the physician is rarely able to make an etiological diagnosis on clinical grounds alone,

271 treatment should ideally be based on the result of bacteriological examination. In this case,
272 bacteriological diagnosis could be complicated by the fact that the respiratory tract could be
273 infected by *K. pneumoniae*²⁸. Although the population we included in our study is young, the
274 clinical signs of a few patients warned us of possible serious infections due to *K. pneumoniae*
275 such as bloody sputum and a chest pain which were among typical signs of pestis
276 pneumonia, however, *Y. pestis* was not found in culture. Typically, the plague is better known
277 by its three clinical forms: bubonic, septicemic and pulmonary plague while hypervirulent *K.*
278 *pneumoniae* strains are known to cause pneumonia, sepsis, liver abscesses and
279 meningitis²⁹⁻³¹.

280 We acknowledge the following limitations of our study. First, we studied a limited number of
281 samples in a short duration of the epidemic, which is far from being representative of all the
282 negative samples for *Y. pestis*. Second, detailed data about clinical characteristics and
283 outcomes were lacking due to the outbreak emergency context. Finally, we did not confirm
284 the virulence of the *K. pneumoniae* strains using mouse models.

285

286 **Conclusions**

287 Although few samples were studied, within a short duration of inclusion (9 days from
288 06/10/17 to 14/10/17), our results show that the plague-suspected patients in fact acquired a
289 pneumonia caused by *K. pneumoniae*. Bacterial identification proved useful for determining
290 the etiology. WGS and AST results showed that among the 12 *K. pneumoniae* isolates, there
291 were ESBL producers and virulent strains. This study shows that during epidemics of plague,
292 clinicians and microbiologists should also consider other pathogens, especially *K.*
293 *pneumoniae* given the fact that the clinical symptoms of respiratory plague can be confused
294 with other pathologies.

295

296

297 **Funding**

298 Internal funding.

299

300 **Competing interests**

301 None.

302

303 **Ethical approval**

304 Not required.

305

306 **Acknowledgements**

307 We are deeply grateful to the curators of the Institut Pasteur MLST system (Paris, France) for
308 importing novel alleles, profiles isolates at <https://bigsd.bpasteur.fr>.

309

310 **Author contributions**

311 A.R., T.C., V.J., S.B., M.R. and J.C. wrote the manuscript. A.R., L.M.A., S.A.R., S.H.R., V.A.,
312 S.R. performed lab experiments. S.A.R, V.A., S.R., M.R completed data collection. A.R.,
313 S.B., V.J., M.R. and J.C. conceived the study. A.R., T.C., S.B., M.R. and J.C. analysed and
314 interpreted data. All authors read and approved the final manuscript.

315

316

317 **References**

318

319 1. Rendremanana, R., Andrianaivoarimanana, V., Nikolay, B. *et al.* Epidemiological
320 characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an
321 outbreak report. *Lancet Infect Dis* **19**, 537–545 (2019).

322 2. WHO. International meeting on preventing and controlling plague: the old calamity still

- 323 has a future. *Wkly Epidemiol Rec* **81**, 278–84 (2006).
- 324 3. Andrianaivoarimanana, V., Piola, P., Wagner, D.M., *et al.* Trends of Human Plague,
325 Madagascar, 1998-2016. *Emerg Infect Dis*. **25**(2):220-228 (2019).
- 326 4. Rodrigues, C., Passet, V., Rakotondrasoa, A. Diallo, T.A., Criscuolo, A., Brisse, S.
327 Description of *Klebsiella africanensis* sp. nov., *Klebsiella variicola* subsp. *tropicalensis* subsp.
328 nov. and *Klebsiella variicola* subsp. *variicola* subsp. nov. *Res Microbiol*. **170**: 165-170 (2019).
- 329 5. Wyres, K.L., Holt, K.E. *Klebsiella pneumoniae* as a key trafficker of drug resistance
330 genes from environmental to clinically important bacteria. *Curr Opin Microbiol*. **45**, 131-139
331 (2018).
- 332 6. Mizuta, K., Ohta, M., Mori, M., Hasegawa, T., Nakashima, I., Kato, N. Virulence for
333 mice of *Klebsiella* strains belonging to the O1 group: relationship to their capsular (K) types.
334 *Infect Immun*. **40**(1):56-61 (1983).
- 335 7. Cortés, G., Borrell, N., de Astorza, B., Gómez, C., Sauleda, J., Albertí, S. Molecular
336 analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side
337 chain to the virulence of *Klebsiella pneumoniae* in a murine model of pneumonia. *Infect*
338 *Immun*. **70**(5):2583-90 (2002).
- 339 8. Tomás, J.M., Camprubi, S., Merino, S., Davey, M.R., Williams, P. Surface exposure
340 of O1 serotype lipopolysaccharide in *Klebsiella pneumoniae* strains expressing different K
341 antigens. *Infect Immun*. **59**(6):2006-11 (1991).
- 342 9. Di Martino, P., Cafferini, N., Joly, B., Darfeuille-Michaud, A. *Klebsiella pneumoniae*
343 type 3 pili facilitate adherence and biofilm formation on abiotic surfaces. *Res Microbiol*.
344 **154**(1):9-16 (2003).
- 345 10. Turton, J. F., Baklan, H., Siu, L. K., Kaufmann, M. E., Pitt, T. L. Evaluation of a
346 multiplex PCR for detection of serotypes K1, K2 and K5 in *Klebsiella* sp. and comparison of
347 isolates within these serotypes. *FEMS Microbiol. Lett*. **284**, 247–252 (2008).
- 348 11. Lin, W. H. *et al.* Clinical and microbiological characteristics of *Klebsiella pneumoniae*

349 isolates causing community-acquired urinary tract infections. *Infection* **38**, 459–464 (2010).

350 12. Shon, A.S., Bajwa, R.P., Russo, T. A. Hypervirulent (hypermucoviscous) *Klebsiella*
351 *pneumoniae*: a new and dangerous breed. *Virulence*. **4**(2):107-18 (2013).

352 13. WHO. Interregional meeting on prevention and control of plague. Geneva: World
353 Health Organization, 2008.

354 14. Passet, V. & Brisse, S. Association of tellurite resistance with hypervirulent clonal
355 groups of *Klebsiella pneumoniae*. *J. Clin. Microbiol.* **53**, 1380–1382 (2015).

356 15. Barbier, E., Rodrigues, C., Depret, G., *et al.* The ZKIR Assay, a Real-Time PCR
357 Method for the Detection of *Klebsiella pneumoniae* and Closely Related Species in
358 Environmental Samples. *Appl Environ Microbiol.* **86**(7):e02711-19 (2020).

359 16. Rajerison, M., Melocco, M., Andrianaivoarimanana, V., Rahajandraibe, S.,
360 Rakotoarimanana, F., *et al.* Performance of plague rapid diagnostic test compared to
361 bacteriology; a retrospective analysis of the data collected in Madagascar. *BMC Infectious*
362 *diseases*. **20**(90) (2020).

363 17. Weagant, S.D. A new chromogenic agar medium for detection of potentially virulent
364 *Yersinia enterocolitica*. *J Microbiol Methods*. 2008 Feb;72(2):185-90. doi:
365 10.1016/j.mimet.2007.11.019. Epub 2007 Dec 4. PMID: 18177960.

366 18. Huynh, B.T., Passet, V., Rakotondrasoa, A., Diallo, T., Kerleguer, A., *et al.* *Klebsiella*
367 *pneumoniae* carriage in low-income countries: antimicrobial resistance, genomic diversity
368 and risk factors. *Gut Microbes*. 2020;11(5):1287-1299 (2020).

369 19. Rakotondrasoa, A., Passet, V., Herindrainy, P., Garin, B., Kermorvant-Duchemin, E.,
370 *et al.* Characterization of *Klebsiella pneumoniae* isolates from a mother-child cohort in
371 Madagascar. *J Antimicrob Chemother.* **75**(7):1736-1746 (2020).

372 20. Tajadini, M., Panjehpour, M., Javanmard, S.H. Comparison of SYBR Green and
373 TaqMan methods in quantitative real-time polymerase chain reaction analysis of four
374 adenosine receptor subtypes. *Adv Biomed Res*. 2014 Feb 28;3:85. doi: 10.4103/2277-

375 9175.127998. PMID: 24761393; PMCID: PMC3988599.

376 21. Fu, Y., Zhang, F., Zhang, W., Chen, X., Zhao, Y., *et al.* Differential expression of
377 bla(SHV) related to susceptibility to ampicillin in *Klebsiella pneumoniae*. *Int J Antimicrob*
378 *Agents*. **29**(3):344-7 (2007).

379 22. Hubbard, A.T.M., Mason, J., Roberts, P., Parry, C.M., Corless, C., *et al.*
380 Piperacillin/tazobactam resistance in a clinical isolate of *Escherichia coli* due to IS26-
381 mediated amplification of bla_{TEM-1B}. *Nat Commun*. **11**(1):4915 (2020).

382 23. Lam, M.M.C., Wyres, K.L., Duchêne, S., Wick, R.R., Judd, L.M., *et al.* Population
383 genomics of hypervirulent *Klebsiella pneumoniae* clonal-group 23 reveals early emergence
384 and rapid global dissemination. *Nat Commun*. **9**(1):2703 (2018).

385 24. Diancourt, L., Passet, V., Verhoef, J., Grimont, P. A. D. & Brisse, S. Multilocus
386 sequence typing of *Klebsiella pneumoniae* nosocomial isolates multilocus sequence typing of
387 *Klebsiella pneumoniae* nosocomial isolates. *J. Clin. Microbiol*. **43**, 4178–4182 (2005).

388 25. Holt, K.E., Wertheim, H., Zadoks, R.N., Baker, S., Whitehouse, C.A., *et al.* Genomic
389 analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella*
390 *pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci*. **112**(27):E3574-81 (2015).

391 26. Liao, C.H., Huang, Y.T., Chang, C.Y., Hsu, H.S., Hsueh, P.R. Capsular serotypes
392 and multilocus sequence types of bacteremic *Klebsiella pneumoniae* isolates associated with
393 different types of infections. *Eur J Clin Microbiol Infect Dis*. **33**(3):365-9 (2014).

394 27. Rakin, A., Schneider, L., Podladchikova, O. Hunger for iron: the alternative
395 siderophore iron scavenging systems in highly virulent *Yersinia*. *Front Cell Infect Microbiol*.
396 **2**:151 (2012).

397 28. Sasaki, E., Tokiwa, T., Tsugo, K., Higashi, Y., Hori, H., *et al.* Peracute Bacterial
398 Meningitis due to Infection with *Klebsiella pneumoniae* in Captive-bred Ruffed Lemurs
399 (*Varecia variegata*). *J Comp Pathol*. **156**(2-3):281-285 (2017).

400 29. Galy, A., Loubet, P., Peiffer-Smadja, N., Yazdanpanah, Y. The plague: An overview

401 and hot topics. *Rev Med Interne*. **39**(11):863-868 (2018).

402 30. Fung, C., Chang, F., Lee, S., Hu, B.S., Kuo, B.I. *et al*. A global emerging disease of
403 *Klebsiella pneumoniae* liver abscess? is serotype K1 an important factor for complicated
404 endophthalmitis. *Gut*. **50**: 420–4 (2002).

405 31. Chung, D.R., Lee, H., Park, M.H., Jung, S.I., Chang, H.H. *et al*. Fecal carriage of
406 serotype K1 *Klebsiella pneumoniae* ST23 strains closely related to liver abscess isolates in
407 Koreans living in Korea. *Eur J Clin Microbiol Infect Dis*. **31**: 481–6 (2012).

408

409

410

Figures

Tree scale: 0.01




Figure 1

Phylogenetic tree of 12 *K. pneumoniae* isolates




Figure 2

Melting curve results from ZKIR region detection obtained after 40 cycles on the ZKIR quantitative PCR system of Kp. DNA from two positive controls from strains blue to UUA 2239, violet to UUA 2016. DNA extracted from patients' buboes in pink to PP2 and red color to PP8. Orange color corresponds to negative control.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table.pdf](#)
- [TableS1.csv](#)